Soligenix (DB:DOA) - Cours de l'action, nouvelles et analyse

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

DOA Aperçu des actions

A late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States.

A propos de l'entreprise

DOA analyse fondamentale
Score flocon de neige
Évaluation	2/6
Croissance future	2/6
Performances passées	0/6
Santé financière	2/6
Dividendes	0/6

Récompenses

Les revenus devraient augmenter 75.85% par an

Analyse des risques

Les bénéfices devraient diminuer en moyenne de 1.5% par an au cours des 3 prochaines années

N'a pas de capitalisation boursière significative ( €9M )

Réalise moins d'un million de dollars de revenus ( $949K )

Capitaux propres négatifs

+ 3 plus de risques

Soligenix, Inc. Concurrents

co.don

XTRA:CNW

€6.5m

Medigene

XTRA:MDG1

€27.6m

bioXXmed

XTRA:T5O

€1.8m

Epigenomics

DB:ECX

€533.8k

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Soligenix
Historique des cours de bourse
Prix actuel de l'action	US$5.85
Plus haut sur 52 semaines	US$14.11
Plus bas sur 52 semaines	US$5.58
Bêta	1.74
1Variation sur 1 mois	0%
Variation sur 3 mois	-5.11%
Variation sur 1 an	-10.53%
3Variation sur 3 ans	-73.29%
Variation sur 5 ans	-71.94%
Évolution depuis l'introduction en bourse	-77.87%

Nouvelles et mises à jour récentes

Recent updates

Rendement pour les actionnaires

	DOA	DE Biotechs	DE Marché
7D	0%	0.2%	1.2%
1Y	-10.5%	-9.2%	16.6%

Rendement vs Industrie: DOA a dépassé le secteur German Biotechs qui a rapporté -22 % au cours de l'année écoulée.

Rendement vs marché: DOA a sous-performé le marché German qui a rapporté 4.7 % au cours de l'année écoulée.

Volatilité des prix

Is DOA's price volatile compared to industry and market?
DOA volatility
DOA Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.0%
10% least volatile stocks in DE Market	2.4%

Cours de l'action stable: DOA n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: Données insuffisantes pour déterminer l'évolution de la volatilité de DOA au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
1987	14	Christopher Schaber	www.soligenix.com

Soligenix, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de Soligenix se comparent-ils à sa capitalisation boursière ?
DOA statistiques fondamentales
Capitalisation boursière	€7.89m
Bénéfices(TTM)	-€12.59m
Recettes(TTM)	€865.50k

9.1x

Ratio P/S

-0.6x

Ratio P/E

Le site DOA est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
DOA compte de résultat (TTM)
Recettes	US$948.91k
Coût des recettes	US$550.82k
Marge brute	US$398.09k
Autres dépenses	US$14.20m
Les revenus	-US$13.80m

Derniers bénéfices déclarés

Dec 31, 2022

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-1.45
Marge brute	41.95%
Marge bénéficiaire nette	-1,454.12%
Ratio dettes/capitaux propres	-400.6%

Quelles ont été les performances à long terme de DOA?

Voir les performances historiques et les comparaisons

DOA Aperçu des actions

Récompenses

Analyse des risques

Soligenix, Inc. Concurrents

XTRA:CNW

€6.5m

XTRA:MDG1

€27.6m

XTRA:T5O

€1.8m

DB:ECX

€533.8k

Historique des prix et performances

Nouvelles et mises à jour récentes

Soligenix, Inc. Announces HyBryte Expanded Treatment Results to Be Presented at the European Organisation for Research and Treatment of Cancer Conference

Soligenix, Inc. Announces Significant Progress in the Treatment of Cutaneous T-Cell Lymphoma with its Investigational Drug, HyBryte™

Soligenix, Inc. Announces an Interim Update on the Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte Treatment for Up to 12 Months in Patients with Early-Stage Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from A Comparative Study Evaluating Hybryte™? Against Valchlor®? in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc., Annual General Meeting, May 23, 2024

Recent updates

Soligenix, Inc. Announces HyBryte Expanded Treatment Results to Be Presented at the European Organisation for Research and Treatment of Cancer Conference

Soligenix, Inc. Announces Significant Progress in the Treatment of Cutaneous T-Cell Lymphoma with its Investigational Drug, HyBryte™

Soligenix, Inc. Announces an Interim Update on the Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte Treatment for Up to 12 Months in Patients with Early-Stage Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from A Comparative Study Evaluating Hybryte™? Against Valchlor®? in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc., Annual General Meeting, May 23, 2024

Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa

Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte™ with the European Medicines Agency

Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board

FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease

Soligenix Announces Top-Line Results of the Phase 2A Study of Sgx302 (Synthetic Hypericin) in Patients with Mild-To-Moderate Psoriasis

Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses

Soligenix Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Rule and Not Eligible for Second 180 Day Period

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in Treatment of Aphthous Ulcers in Behçet's Disease

Soligenix, Inc. Announces HyBryte(TM) Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment

Soligenix, Inc., Annual General Meeting, Sep 21, 2023

Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis

Timothy R. Coté Resigned as A Member of the Board of Directors of Soligenix, Inc

Soligenix Regains Compliance with the Shareholders’ Equity Requirement and in Compliance with All Other Applicable Requirements for Listing on Nasdaq

Soligenix, Inc. Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Appointment of Timothy R. Coté, M.D. to Its Board of Directors

Soligenix, Inc. Receives Refusal to File Letter from U.S. FDA for Hybryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Publication Demonstrating Positive Correlates of Protection with Rivax® in Non-Human Primate Survival After Ricin Challenge

Soligenix, Inc. Initiates Phase 2 Clinical Trial of SGX302 (Synthetic Hypericin) for the Treatment of Mild-To-Moderate Psoriasis

Soligenix Announces Submission of New Drug Application to the FDA for Hybryte™ in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Receives Non Compliance Notice from Nasdaq

Third quarter 2022 earnings released: US$0.077 loss per share (vs US$0.088 loss in 3Q 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.077 loss per share (vs US$0.088 loss in 3Q 2021)

Soligenix, Inc. Announces U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Second quarter 2022 earnings released: US$0.055 loss per share (vs US$0.047 loss in 2Q 2021)

Soligenix, Inc., Annual General Meeting, Sep 22, 2022

Soligenix, Inc. Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces HyBryte™ Phase 3 FLASH Study for the Treatment of Cutaneous T-Cell Lymphoma Published in JAMA Dermatology

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in Treatment of Psoriasis

Soligenix Announces Successful Protection Using A Bivalent Thermostabilized Filovirus Vaccine

Soligenix Receives US Patent Allowance for Its Thermostabilized Vaccine Platform

First quarter 2022 earnings released: US$0.10 loss per share (vs US$0.064 loss in 1Q 2021)

Insufficient new directors

No longer forecast to breakeven

Full year 2021 earnings released: US$0.31 loss per share (vs US$0.64 loss in FY 2020)

Soligenix, Inc. Demonstrates Positive Anti-Tumor Efficacy in Multiple Nonclinical Animal Studies

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.088 loss per share (vs US$0.061 loss in 3Q 2020)

Insufficient new directors

Rendement pour les actionnaires

Volatilité des prix

À propos de l'entreprise

Soligenix, Inc. Résumé des fondamentaux

9.1x

-0.6x

Bénéfices et recettes